Bridge BioResearch Announces the Granting of US Patent for CD14
Bridge Bioresearch PLC (BBR) announces that the company has been granted the US patent for their CD14 molecule indicated for treatment of Diabetes Type 2, obesity, atherosclerosis as well as inflammatory diseases.
Originally acquired from the Spanish Biotech company Mellitus, BBR has continued research in animal models verifying pharmacological properties of the CD14 molecule. BBR has now achieved the granting of the US patent, which according to Mr. Soren Stenderup, CEO of BBR, further strengthens the IP position of CD14 as this complements the already issued European patent.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
European Health Technology Institute for Socio-Economic Research - Brüssel, Belgium
MorphoSys Announces Clinical Milestone from Strategic Alliance - Third HuCAL Antibody to Enter Clinical Trials in 2010

Flanschenwerk Bebitz GmbH - Bebitz, Germany
New cell division mechanism discovered
ThromboGenics Announces Publication of Positive Microplasmin Phase II Data
Genzyme Receives European Label Expansion for Thyrogen

Nasal spray could deliver a future mRNA vaccine against COVID-19 - The researchers aim to design a biomimetic nanoparticle that deceives the body's immune cells to act as if they had encountered a true virus
